Patents by Inventor Barbara Jagodzinska

Barbara Jagodzinska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11370793
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 28, 2022
    Assignee: NantNeuro, LLC
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Publication number: 20220162198
    Abstract: Compositions and methods of use for a compound having a chemical structure of Formula (I) and/or Formula (VII), or a pharmaceutically acceptable salt or solvate thereof, to increase muscle mass, muscle oxidative capacity, and muscle function and to treat muscular dystrophy, in particular limb girdle muscular dystrophy type 2A/R1/D1 are disclosed.
    Type: Application
    Filed: April 9, 2020
    Publication date: May 26, 2022
    Applicant: The Regents of the University of California
    Inventors: Melissa SPENCER, Varghese JOHN, Irina KRAMEROVA, Jian LIU, Jesus CAMPAGNA, Barbara JAGODZINSKA
  • Publication number: 20220041553
    Abstract: Disclosed herein are compounds, compositions, and methods for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: February 11, 2021
    Publication date: February 10, 2022
    Inventors: Barbara Jagodzinska, Jesus Campagna, Johnny Pham, Michael E. Jung, Varghese John, Rammonhan Rao, Dale E. Bredesen, Veena P. Theendakara
  • Publication number: 20220024935
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 27, 2022
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 11142505
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 11077108
    Abstract: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: August 3, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Barbara Jagodzinska
  • Publication number: 20210101879
    Abstract: The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC50 values and permeability across the blood-brain barrier.
    Type: Application
    Filed: February 28, 2019
    Publication date: April 8, 2021
    Inventors: John Varghese, Barbara Jagodzinska, Jesus Campagna
  • Publication number: 20200270216
    Abstract: Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods of using the disclosed compounds and compositions for inhibiting the spread of Tau seeds from donor cells to recipient cells. Moreover, disclosed herein are methods of using the disclosed compounds and compositions for treating or preventing a neurodegenerative disorder, such as a tauopathy, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 27, 2020
    Inventors: Tina Bilousova, Barbara Jagodzinska, Varghese John
  • Publication number: 20190307747
    Abstract: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models.
    Type: Application
    Filed: September 6, 2017
    Publication date: October 10, 2019
    Inventors: Mohammad Parvez Alam, Varghese John, Barbara Jagodzinska
  • Publication number: 20190134000
    Abstract: In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of compound C41 to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly enhances sAPP?, lowers A?, p-Tau, inhibits the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (APP664) and improves memory in a mammal are provided.
    Type: Application
    Filed: May 11, 2017
    Publication date: May 9, 2019
    Inventors: Varghese John, Dale E. Bredesen, Patricia R. Spilman, Barbara Jagodzinska
  • Publication number: 20190077766
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Publication number: 20190048012
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 14, 2019
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Publication number: 20170226059
    Abstract: A link between ApoE4 allele and sirtuins expression level is identified that is believed to be associated with elevated risk for the promotion of processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway in a mammal leading to elevated risk for Alzheimer's disease. Compounds are identified that upregulate sirtuins (e.g., SirT1) expression levels and appear to be useful in the treatment and/or prophylaxis of MCI and/or Alzheimer's disease.
    Type: Application
    Filed: August 19, 2015
    Publication date: August 10, 2017
    Inventors: Barbara Jagodzinska, Jesus Campagna, Johnny Pham, Michael E. Jung, Varghese John, Rammohan Rao, Dale E. Bredesen, Veena P. Theendakara
  • Patent number: 7906556
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: March 15, 2011
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: R. Jeffrey Neitz, Eric Tisdale, Barbara Jagodzinska, Anh Truong, Jay Tung
  • Patent number: 7858642
    Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 28, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, John Tucker, Jose Aquino, Barbara Jagodzinska, Louis Brogley, Jay S. Tung, Simeon Bowers, Darren Dressen, Gary Probst, Neerav Shah
  • Patent number: 7727997
    Abstract: Disclosed are compounds of the formula wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of disorders such as Alzheimer's Disease.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: June 1, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, James Beck, Andrea Gailunas, John Freskos, John Mickelson, Lakshman Samala, Jennifer Sealey, Ruth Tenbrink, Larry Fang, Roy Hom
  • Publication number: 20090270367
    Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: March 3, 2009
    Publication date: October 29, 2009
    Inventors: Varghese JOHN, Michel MAILLARD, John TUCKER, Jose AQUINO, Barbara JAGODZINSKA, Louis BROGLEY, Jay TUNG, Simeon BOWERS, Darren DRESSEN, Gary PROBST, Neerav SHAH
  • Patent number: 7498436
    Abstract: This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: March 3, 2009
    Assignees: Pharmacia & Upjohn Company LLC, Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Barbara Jagodzinska, Michel Maillard, James P. Beck, Ruth E. TenBrink, Daniel Getman
  • Publication number: 20090042961
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: May 8, 2008
    Publication date: February 12, 2009
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • Publication number: 20080161325
    Abstract: The present invention relates to compounds of formula (AA) (I) and (X): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
    Type: Application
    Filed: November 13, 2007
    Publication date: July 3, 2008
    Inventors: Yvette M. Fobian, John N. Freskos, Barbara Jagodzinska